Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
Department of Radiation Oncology, Yamatotakada Municipal Hospital, Nara 635-8501, Japan.
J Radiat Res. 2024 Mar 22;65(2):223-230. doi: 10.1093/jrr/rrad103.
The present study aimed to evaluate whether an adapted plan with Ethos™ could be used for pharyngeal cancer. Ten patients with pharyngeal cancer who underwent chemoradiotherapy with available daily cone-beam computed tomography (CBCT) data were included. Simulated treatments were generated on the Ethos™ treatment emulator using CBCTs every four to five fractions for two plans: adapted and scheduled. The simulated treatments were divided into three groups: early (first-second week), middle (third-fourth week), and late (fifth-seventh week) periods. Dose-volume histogram parameters were compared for each period between the adapted and scheduled plans in terms of the planning target volume (PTV) (D98%, D95%, D50% and D2%), spinal cord (Dmax and D1cc), brainstem (Dmax) and ipsilateral and contralateral parotid glands (Dmedian and Dmean). The PTV D98%, D95% and D2% of the adapted plan were significantly higher than those of the scheduled plans in all periods, except for D98% in the late period. The adapted plan significantly reduced the spinal cord Dmax and D1cc compared with the scheduled plan in all periods. Ipsilateral and contralateral parotid glands Dmean of the adapted plan were lower than those of scheduled plan in the late period. In conclusion, the present study revealed that the adapted plans could maintain PTV coverage while reducing the doses to organs at risk in each period compared with scheduled plans.
本研究旨在评估 Ethos™ 是否可以用于治疗咽癌。纳入了 10 名接受放化疗且有每日锥形束 CT(CBCT)数据的咽癌患者。利用 CBCT 对 Ethos™ 治疗模拟器生成了两个计划(适应性计划和计划)的模拟治疗:每四到五次分次进行治疗。将模拟治疗分为三个时期:早期(第一至第二周)、中期(第三至第四周)和晚期(第五至第七周)。在每个时期,将适应性计划和计划的剂量-体积直方图参数(PTV(D98%、D95%、D50% 和 D2%)、脊髓(Dmax 和 D1cc)、脑干(Dmax)和同侧及对侧腮腺(Dmedian 和 Dmean))进行比较。适应性计划的 PTV D98%、D95% 和 D2%在所有时期均明显高于计划,除晚期 PTV D98% 外。适应性计划在所有时期均显著降低脊髓 Dmax 和 D1cc 与计划相比。与计划相比,适应性计划在晚期同侧和对侧腮腺 Dmean 较低。总之,本研究表明与计划相比,适应性计划可以在每个时期维持 PTV 覆盖的同时降低危及器官的剂量。